South African Medical News

Back to Home Page

Print using browser
Boehringer Ingelheim launch Jardiance 10 mg and 25 mg tablets (empagliflozin)


Dear Healthcare Provider

Boehringer Ingelheim announces the launch of JARDIANCE®, an SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor) in South Africa. 


* This is a drug - read the leaflet carefully before use. 

* Ask your doctor or pharmacist for further information. 

Boehringer Ingelheim thank you for your continued support.

For full prescribing information please refer to package insert approved by the Medical Regulatory Authority.
Boehringer Ingelheim (Pty) Ltd, 407 Pine Ave, Randburg

S4 JARDIANCE® 10 mg: Each film-coated tablet contains empagliflozin 10 mg. Reg. No. 48/21.2/1380.
S4 JARDIANCE® 25 mg: Each film-coated tablet contains empagliflozin 25 mg. Reg. No. 48/21.2/0411.

You need to be logged in to see more details. Register Now!

Click here to visit the Boehringer Ingelheim website....
Contact: Sarojini Moodley, Product Manager
Telephone: +27 (0) 11 348 2400
Date: Tuesday, May 1, 2018